

Mehdi Bouhaddou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6953503/publications.pdf>

Version: 2024-02-01

27
papers

6,762
citations

516215

16
h-index

610482

24
g-index

42
all docs

42
docs citations

42
times ranked

13136
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. <i>Life Science Alliance</i> , 2022, 5, e202101200.	1.3	26
2	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
3	A functional map of HIV-host interactions in primary human T cells. <i>Nature Communications</i> , 2022, 13, 1752.	5.8	27
4	Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs. , 2022, 235, 108162.		5
5	Evolution of enhanced innate immune evasion by SARS-CoV-2. <i>Nature</i> , 2022, 602, 487-495.	13.7	237
6	Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. <i>Cell</i> , 2021, 184, 106-119.e14.	13.5	320
7	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. <i>Science</i> , 2021, 371, 926-931.	6.0	247
8	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. <i>Science</i> , 2021, 374, eabf2911.	6.0	37
9	A protein interaction landscape of breast cancer. <i>Science</i> , 2021, 374, eabf3066.	6.0	66
10	Predicting <i>In Vivo</i> Efficacy from <i>In Vitro</i> Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 419-429.	1.5	16
11	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. <i>Science</i> , 2020, 370, .	6.0	508
12	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. <i>Cell</i> , 2020, 182, 685-712.e19.	13.5	825
13	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <i>Nature</i> , 2020, 583, 459-468.	13.7	3,542
14	The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2. <i>Cancer Discovery</i> , 2020, 10, 916-921.	7.7	44
15	Mapping the protein-protein and genetic interactions of cancer to guide precision medicine. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 110-117.	1.5	15
16	Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. <i>ACS Chemical Neuroscience</i> , 2018, 9, 118-129.	1.7	17
17	Fluorescence Multiplexing with Spectral Imaging and Combinatorics. <i>ACS Combinatorial Science</i> , 2018, 20, 653-659.	3.8	15
18	Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array. <i>Scientific Reports</i> , 2018, 8, 11329.	1.6	14

#	ARTICLE	IF	CITATIONS
19	A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens. PLoS Computational Biology, 2018, 14, e1005985.	1.5	45
20	Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma. PLoS ONE, 2018, 13, e0190664.	1.1	10
21	Abstract 2796: Predicting in vivo efficacy from in vitro data: Quantitative systems pharmacology modeling for an epigenetic modifier drug in cancer. , 2018, , .		0
22	A Comparison of mRNA Sequencing with Random Primed and 3â€²-Directed Libraries. Scientific Reports, 2017, 7, 14626.	1.6	52
23	Abstract 1568: Predicting stochastic proliferation and death in response to drugs with mechanistic models tailored to genomic, transcriptomic, and proteomic data. , 2017, , .		0
24	Drug response consistency in CCLE and CGP. Nature, 2016, 540, E9-E10.	13.7	64
25	Kinetic Models of Biochemical Signaling Networks. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 105-135.	0.2	1
26	Engineered Mammalian RNAi Can Elicit Antiviral Protection that Negates the Requirement for the Interferon Response. Cell Reports, 2015, 13, 1456-1466.	2.9	32
27	Dimerization-based control of cooperativity. Molecular BioSystems, 2014, 10, 1824-1832.	2.9	15